Liquidia Corporation (LQDA)
NASDAQ: LQDA · Real-Time Price · USD
23.62
+2.42 (11.42%)
Aug 12, 2025, 11:56 AM - Market open
Paramount Global Employees
Liquidia had 170 employees as of December 31, 2024. The number of employees increased by 25 or 17.24% compared to the previous year.
Employees
170
Change (1Y)
25
Growth (1Y)
17.24%
Revenue / Employee
$83,200
Profits / Employee
-$815,753
Market Cap
2.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 170 | 25 | 17.24% |
| Dec 31, 2023 | 145 | 82 | 130.16% |
| Dec 31, 2022 | 63 | 11 | 21.15% |
| Dec 31, 2021 | 52 | 1 | 1.96% |
| Dec 31, 2020 | 51 | -13 | -20.31% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LQDA News
- 5 hours ago - Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - What Next For Liquidia After Launch? - Seeking Alpha
- 7 weeks ago - Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™ - GlobeNewsWire
- 2 months ago - Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - GlobeNewsWire
- 2 months ago - These Analysts Boost Their Forecasts On Liquidia - Benzinga
- 2 months ago - Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire
- 3 months ago - Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - GlobeNewsWire